Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
Author:
Affiliation:
1. Imperial College London; National Heart and Lung Institute; London UK
2. St George's, University of London; Population Health Research Institute; Cranmer Terrace London UK SW17 0RE
Publisher
Wiley
Subject
Pharmacology (medical)
Reference173 articles.
1. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment;Aaron;Canadian Respiratory Journal,2004
2. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial;Aaron;Annals of Internal Medicine,2007
3. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD;Kaplan;Primary Care Respiratory Journal,2007
4. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD;Najafzadeh;Thorax,2008
5. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial;Roisman;Revue de Pneumologie Clinique,2007
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. New clinical guidelines for COPD – a paradigm shift: A review;Terapevticheskii arkhiv;2024-04-16
2. Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease;Frontiers in Medicine;2024-02-13
3. Comorbidities in COPD: Current and Future Treatment Challenges;Journal of Clinical Medicine;2024-01-27
4. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease;Cochrane Database of Systematic Reviews;2023-12-06
5. Impact of pharmacological and non-pharmacological interventions on mortality in chronic obstructive pulmonary disease (COPD) patients;Respiratory Medicine and Research;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3